News and Announcements
Biorithm nominated for Top 20 in “Creating the New Normal” sector of Startup SG’s Slingshot Competition 2020
- Published January 07, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Biorithm, a startup based in Singapore was awarded a spot in the Top 20 finalists of Startup SG’s Slingshot Competition’s “COVID-19 Challenge: Creating the New Normal” sector. In addition, they made it to the Top 100 Finalists overall, representing one of the Top 20 innovative startups in the MedTech, HealthTech & BioTech sector.
The Slingshot competition is an annual startup competition powered by Startup SG and organized by Enterprise Singapore. This year was its fourth annual edition, and due to the pandemic, the finals at SFF x SWITCH 2020 (Singapore FinTech Festival x Singapore Week of Innovation and Technology) were held virtually to accommodate its very global participants.
This year, the competition was also global and as a result, highly competitive. Biorithm competed with over 7,500 other innovative and globally based startups to receive its place in the Top 20 of two widely sought-out challenge sectors. The Top 100 start-ups were invited for a week of mentorship and pitch clinics, called Gear-Up, which prepared them for the three-day virtual finals.
[Pitch video from Slingshot]
About Biorithm
Biorithm provides innovative maternal-fetal connected care solution to improve pregnancy outcomes for patients and healthcare providers.
Forging new frontiers in pregnancy care, Biorithm has developed cutting edge analytic software together with medical-grade abdominal ECG wearable designed for remote monitoring of maternal & fetal physiological parameters.
Our unique solution allows accurate monitoring of a wide range of vital pregnancy data, empowering patient and clinicians to identify early signs of maternal-fetal complication for timely intervention while reducing the cost of care.
Founded by doctors and engineers, Biorithm is a medical technology start-up spun-off from Nanyang Technological University in Singapore. We believe that comprehensive maternal healthcare should leverage the power of digital health and advanced sensors to address individual patient and clinicians needs, enhance data-driven decisions, complication prevention, and provide access to affordable and preventive care.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
